Locally advanced prostate cancer is stage ≥T3NX/+M0. Untreated, these men are at significant risk of disease progression and cancer-specific death; fewer now present at this stage because of screening. Two options carry a proven overall-survival benefit: radiation with long-term ADT, and radical prostatectomy with extended pelvic lymphadenectomy.
Radical Prostatectomy
Surgery is generally reserved for high-risk, low-volume tumours that can be completely excised. Prostatectomy alone is often insufficient, but some men with high-risk features are cured by surgery alone, and adjuvant or combined therapy may further improve outcomes. Non-surgical modalities are increasingly used for high-risk disease.
Prognosis — 15-year outcomes in men found to have positive nodes (pN1) after radical prostatectomy:
| Outcome | 15-year rate |
|---|---|
| Biochemical-recurrence-free survival | 7.1% |
| Metastasis-free survival | 41.5% |
| Cancer-specific survival | 57.5% |
Neoadjuvant and adjuvant ADT are addressed under Management of Localized Prostate Cancer; outside of N+ disease (see pN1 management below), evidence for adjuvant ADT in locally advanced tumours is limited.
Radiation After Prostatectomy
Men with extraprostatic extension (pT3a), seminal vesicle invasion (pT3b), or positive surgical margins may harbour residual cancer cells in the prostatic bed that postoperative radiotherapy can eradicate.
Adjuvant vs Salvage Timing
- Adjuvant radiotherapy is given proactively shortly after surgery while the PSA is undetectable.
- Salvage radiotherapy is given once the postoperative PSA is detectable; radiation for a persistent post-prostatectomy PSA is salvage, not adjuvant, and men with adverse pathology and a persistent PSA should be offered salvage RT.
- Arguments for adjuvant: most effective when tumour burden is smallest, requires a lower radiation dose, and needs less ADT.
- Arguments for early salvage: avoids overtreating men who would never recur (most focally positive margins ± extraprostatic extension are cured by surgery), and PSA is sensitive enough that little is lost by monitoring PSA velocity — particularly with limited life expectancy or Gleason 6–7 disease.
- Adjuvant toxicity: 5–10% risk of radiation proctitis or cystitis and a 50% risk of erectile dysfunction.
Adjuvant Radiation vs Observation
Three RCTs showed improved biochemical-recurrence-free and cancer-specific survival with adjuvant radiation versus observation for locally advanced / positive-margin disease:
| Trial | Population | Key result |
|---|---|---|
| SWOG 8794 (Thompson 2009) | 431 men, pT3 ± positive margins | Improved metastasis-free survival (14.7 vs 12.9 yr) and overall survival (15.2 vs 13.3 yr); NNT 9.1 to prevent one death at ~12.6 yr |
| EORTC 22911 (Bolla 2012) | 1,005 men, pT3 ± positive margins | Biochemical PFS improved 21% at 5 yr (74% vs 53%); lower locoregional failure (5.4% vs 15.4%); no OS difference; benefit driven by the positive-margin subset (HR 0.38) |
| ARO 96-02 (Wiegel 2014) | 368 men, pT3/pT4, N0, all undetectable PSA | Biochemical PFS improved 21% at 10 yr (56% vs 35%); no metastasis-free or overall survival benefit |
A systematic review of these three trials found immediate RT reduces recurrence in aggressive disease at the cost of increased acute (15–35%) and late (2–8%) toxicity.
Adjuvant vs Early Salvage Radiation
Early salvage radiation means monitoring PSA and treating only on convincing progression. It works best at low PSA — salvage RT started at PSA ≤0.5 ng/mL gives better 5-year biochemical PFS than starting above 0.5 — and the benefit is strongest in men with the shortest PSA doubling times (<6 months).
- The ARTISTIC meta-analysis (Vale 2020) pooled RADICALS, GETUG-17, and RAVES (2,153 men) and found no difference in event-free survival between adjuvant RT and surveillance with early salvage (HR 0.95, 95% CI 0.75–1.21), with more genitourinary toxicity in the adjuvant arm — though few men had high-risk features.
- RADICALS-RT (Parker 2020) — 1,396 men with ≥1 risk factor (pT ≥3, grade group ≥2, positive margins, or preoperative PSA ≥10) showed no significant difference in 5-year biochemical PFS (85% adjuvant vs 88% salvage).
- GETUG-17 is comparing immediate adjuvant RT with salvage RT at PSA 0.2 ng/mL; RAVES (pT3 ± positive margins) was terminated for poor accrual.
Guideline Recommendations
| Body | Recommendation |
|---|---|
| NCCN 2023 | Life expectancy ≤5 yr → observe; >5 yr → adjuvant RT for pT3a, positive margins, or seminal vesicle involvement (positive margins benefit most). Salvage RT for a PSA that becomes detectable and rises on two measurements, or a persistently detectable PSA. More effective when pre-treatment PSA is low and PSADT long. |
| AUA 2023 (localized) | Adjuvant RT not routinely recommended; manage initially with PSA surveillance; possible role with high-risk features (Gleason 8–10 with extraprostatic extension, positive nodes). |
| AUA 2019 | Offer adjuvant RT for pT3a, positive margins, or seminal vesicle involvement; offer salvage RT for PSA or local recurrence without distant metastases. |
| EAU 2022 | Adjuvant IMRT/VMAT + IGRT only for high-risk pN0 men with ≥2 of 3 features (ISUP grade 4–5, pT3, positive margins). For PSA persistence >0.2 ng/mL, obtain a PSMA-PET if it will change management and treat non-metastatic disease with salvage RT + hormonal therapy. For BCR, offer early salvage RT at two consecutive PSA rises without waiting for a threshold; give ≥64 Gy as soon as possible. |
Management of pN1 Disease
The natural history is heterogeneous — up to 30% of men remain free of disease long term without further therapy (one cohort of 369 pN1 men found 28% biochemical-recurrence-free at 10 years). Three options exist: observation, ADT, and EBRT + ADT.
- ADT — ECOG 7887/3886 (Messing; 98 men with nodal metastases after prostatectomy + lymph node dissection) showed immediate ADT improved disease-free, cancer-specific, and overall survival; the trial was underpowered (100 of a planned 240 enrolled) and the effect size has not been reproduced in larger cohorts. The EORTC trial (Schröder; 302 pN1–3M0 men without local treatment) found no significant OS difference (7.6 vs 6.1 yr; NNT 20.8 at 5 years).
- EBRT + ADT — National Cancer Database studies found EBRT + ADT improved biochemical-recurrence-free, cancer-specific, and overall survival versus ADT alone. Risk-stratify by number of positive nodes and postoperative PSA: with an undetectable PSA consider surveillance with early salvage (adjuvant ADT/RT are alternatives); with a detectable PSA, salvage ADT is recommended. Optimal timing remains unknown.
Radiation With Long-Term ADT
EBRT, or EBRT plus brachytherapy, with concurrent long-term ADT (18–36 months) is recommended (NCCN). The localized-disease trials (EORTC 22863, RTOG 86-10, PR3/PR07, SPCG-7/SFUO-3 — see Management of Localized Prostate Cancer) established that ADT alone is inferior to ADT plus radiation, and the method of ADT does not affect the combined-treatment outcome. Chemotherapy with radiation is less well studied than chemotherapy with surgery.
Primary ADT
ADT monotherapy has not been conclusively shown to improve overall survival in locally advanced disease. In the Bicalutamide Early Prostate Cancer Programme (Iversen 2010; 3,292 men T1b–4 N0/Nx M0 after prostatectomy or radiotherapy, including 657 with locally advanced disease), bicalutamide 150 mg daily improved progression-free survival in the locally advanced subgroup (HR 0.67) without an OS difference, while in the localized subgroup it gave no PFS benefit and an almost significant reduction in OS (HR 1.15).
The ideal PSA threshold for starting ADT is unknown. Both the MRC trial (934 men) and EORTC 30891 (986 men unsuitable for local treatment) found immediate ADT improved overall survival versus delayed ADT, though the EORTC benefit was small and did not extend to cancer-specific mortality. Bicalutamide 150 mg preserved sexual interest and physical capacity better than castration.
Focal Ablative Therapy
Cryotherapy or HIFU may have a role even in locally advanced disease, most likely combined with ADT or other systemic therapy (see Management of Localized Prostate Cancer).
Self-Test
-
What is the definition of locally advanced prostate cancer? Stage T3NX/+M0.
-
Which treatments for locally advanced disease have a proven overall-survival benefit? Radiation with long-term ADT, and radical prostatectomy with extended pelvic lymphadenectomy.
-
What is the dose of bicalutamide when used as monotherapy for locally advanced prostate cancer? 150 mg orally daily.